Products for Research Use Only
RegisterLogin

Tranexamic acid

CAT: 0804-HY-B0149-01Size: 500 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0149-01Size:500 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis. Tranexamic acid is a PROTAC linker. Tranexamic acid is used to synthesize PROTACs (e.g. LZ-07 )[2][3][4][5][6].
CAS Number
1197-18-8
Product Name Alternative
Cyclocapron
UNSPSC
12352211
Hazard Statement
H315, H319, H335
Target
AMPK; IGF-1R; Mitophagy; MMP; PROTAC Linkers
Type
Reference compound
Related Pathways
Autophagy; Epigenetics; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; PROTAC; Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Neurological Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/Tranexamic-acid.html
Purity
99.88
Solubility
DMSO : < 1 mg/mL|H2O : 50 mg/mL (ultrasonic)
Smiles
O=C([C@H]1CC[C@H](CN)CC1)O
Molecular Formula
C8H15NO2
Molecular Weight
157.21
Precautions
H315, H319, H335
References & Citations
[1]Prudovsky I, et al. Tranexamic acid suppresses the release of mitochondrial DNA, protects the endothelial monolayer and enhances oxidative phosphorylation [J]. Journal of cellular physiology, 2019, 234 (11) : 19121-19129.|[2]Wu G, et al. Tranexamic acid is an active site inhibitor of urokinase plasminogen activator [J]. Blood advances, 2019, 3 (5) : 729-733.|[3]Draxler D F, et al. Tranexamic acid modulates the cellular immune profile after traumatic brain injury in mice without hyperfibrinolysis [J]. Journal of Thrombosis and Haemostasis, 2019, 17 (12) : 2174-2187.|[4]Hiramoto K, et al. The amelioration effect of tranexamic acid in wrinkles induced by skin dryness [J]. Biomedicine & Pharmacotherapy, 2016, 80: 16-22.|[5]Sindet-Pedersen S, et al. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery [J]. New England Journal of Medicine, 1989, 320 (13) : 840-843.|[6]Zhen Li, et al., Developing potent anti-inflammatory IRAK4-targeting PROTACs with simplified CRBN ligands, Chinese Chemical Letters, 2025, 111033, ISSN 1001-8417.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
MMP-1

Related Products

CatalogName
HY-140589Acid-PEG4-S-PEG4-acid
HY-140112-01Acid-PEG2-SS-PEG2-acid
HY-140113-01Acid-PEG3-SS-PEG3-acid
HY-W096114-01Acid-PEG8-S-S-PEG8-acid
HY-140114-01Acid-PEG4-S-S-PEG4-acid
HY-N8563Masticadienonic acid
HY-N8543Gliocladic acid
HY-N17650Salviamarinic acid A
HY-N16388α-Costic acid
HY-N15317-01Phocaecholic acid

Alternative Products

CatalogName
022052Tranexamic Acid

Popular Products